Member Type: Diagnostic Companies
Alacris Theranostics, a Berlin-based company, applies a new, revolutionary approach designated ModCellTM to match patients to therapies and therapies to patients. This approach was originally developed at the Max Planck Institute for Molecular Genetics in Berlin and is exclusively licensed to Alacris Theranostics. ModCellTM conducts a much more detailed analysis of the patient and their tumour, based on a complete sequence of genomes of both the tumour and the patient, as well as an exhaustive analysis of the sequences which are read out of the genome of the tumour (the tumour transcriptome). This information – billions of times more detailed than the information normally used to identify patients who should not be treated with a specific drug – is then used to create a detailed model of the individual patient and their tumour, termed the ‘Virtual Patient’ model. This allows a much more detailed prediction of the good, but also the harm, a specific drug could cause in a particular patient.